Your browser is no longer supported. Please, upgrade your browser.
AbbVie Inc.
IndexS&P 500 P/E54.20 EPS (ttm)1.10 Insider Own0.10% Shs Outstand1.59B Perf Week-2.05%
Market Cap95.03B Forward P/E11.92 EPS next Y5.00 Insider Trans-0.64% Shs Float1.57B Perf Month-1.21%
Income1.77B PEG3.52 EPS next Q0.85 Inst Own72.70% Short Float0.91% Perf Quarter-13.19%
Sales19.96B P/S4.76 EPS this Y-57.20% Inst Trans0.27% Short Ratio1.48 Perf Half Y9.47%
Book/sh1.09 P/B54.70 EPS next Y13.86% ROA6.20% Target Price68.64 Perf Year22.83%
Cash/sh5.25 P/C11.35 EPS next 5Y15.40% ROE43.50% 52W Range44.49 - 70.23 Perf YTD-8.21%
Dividend2.04 P/FCF344.30 EPS past 5Y-17.80% ROI16.80% 52W High-15.11% Beta-
Dividend %3.42% Quick Ratio1.30 Sales past 5Y7.00% Gross Margin78.20% 52W Low34.00% ATR1.40
Employees26000 Current Ratio1.40 Sales Q/Q6.70% Oper. Margin19.20% RSI (14)46.25 Volatility1.25% 2.30%
OptionableYes Debt/Eq8.62 EPS Q/Q-172.90% Profit Margin8.90% Rel Volume0.77 Prev Close60.46
ShortableYes LT Debt/Eq6.06 EarningsJan 30 BMO Payout149.50% Avg Volume9.65M Price59.62
Recom2.40 SMA201.04% SMA50-4.32% SMA2002.33% Volume7,387,710 Change-1.39%
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-15-13Reiterated R. F. Lafferty Buy $47.90 → $61
Apr-29-13Reiterated Barclays Equal Weight $41 → $44
Apr-15-13Reiterated Barclays Equal Weight $37 → $41
Mar-01-15 11:15PM  Amgen Biosimilar Rheumatoid Arthritis Therapy Shows Positive Results at The Wall Street Journal
Feb-27-15 02:48PM  Doctor Panel to Weigh Hepatitis C Drugs Costs in Guidelines at Bloomberg
01:04PM  ABBVIE INC. Financials EDGAR Online Financials
Feb-26-15 04:48PM  AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting PR Newswire
03:55PM  Health Care Stocks Flexing Their Muscle at Forbes
01:58PM  Cyberonics Soars On Earnings Beat, Tax Inversion Deal at Investor's Business Daily
11:08AM  6 reasons biotech stocks may soon tank at MarketWatch
08:00AM  AbbVie Launches to Educate Spanish-Speaking Americans about Hypothyroidism and the Importance of Dialogue between Patient and Healthcare Professional PR Newswire
Feb-25-15 07:56PM  The hot health care stocks to buy now for your 401(K) Fox Business Video
06:00PM  Making Money With Charles Payne: 02/25/15 at Fox Business
03:34PM  Heavy News Day For Several Biotech Stocks Benzinga
10:38AM  Gilead & AbbVie: It Doesn't Matter Which Drug is Better, Just Who Will Pay at
08:22AM  AbbVie to Present at Cowen 35th Annual Health Care Conference PR Newswire
03:31AM  Biosimilar copies of blockbuster drug launch in major EU markets Reuters
Feb-24-15 07:50PM  The Best Phone You Cant Get in America at MarketWatch
Feb-23-15 04:45PM  Is Express Scripts 2015 Guidance Good Enough For All-Time Highs? at 24/7 Wall St.
11:56AM  Gilead Sciences: Uh Oh, AbbVie Might Be Doing Better Than We Thought at
11:02AM  Results from AbbVie's Study of VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) Published Online in JAMA; Sub-analyses to be Presented at the PR Newswire
Feb-21-15 12:01AM  Aristocrats Keep Payouts Rising at
Feb-20-15 05:45PM  Stock Pops & Drops: ANN, ABBV, BA & EOG CNBC
03:19PM  ABBVIE INC. Files SEC form 10-K, Annual Report EDGAR Online
02:37PM  Street Talk: ABBV, ARII, DSW, MRVL & JAZZ CNBC
01:09PM  A 'Great Entry Point' for AbbVie; Pfizer a 'Value Creation Machine' at
12:00PM  Will Express Scripts (ESRX) Beat Q4 Earnings Estimates? - Analyst Blog Zacks
08:09AM  D.E. Shaw ups its position in AbbVie Market Realist
12:37AM  Shire PLC (ADR), Allergan, Inc., Time Warner Cable Inc: John Paulsons Top Merger Picks at Insider Monkey
Feb-19-15 12:38PM  AbbVie Boosts Dividend 4% at
12:12PM  AbbVie Increases Quarterly Dividend PR Newswire
Feb-18-15 08:50AM  Neurocrine Biosciences Announces New Offering at 24/7 Wall St.
Feb-17-15 02:15PM  AbbVie: Amgen Circa 2011? at
12:31PM  Fidelity Adds to Apple, Cuts AbbVie Shares, Exits GrubHub at Bloomberg
11:45AM  Why Gilead Sciences Doesn't Seem Too Worried About AbbVie's Hep-C Treatment at
Feb-15-15 07:33AM  Monday interview: Flemming Ornskov, Shire CEO at Financial Times
Feb-13-15 10:31AM  Gilead Sciences: Hepatitis-C Tracking at High End of Guidance, RBC Says at
09:54AM  Shire Misses on Q4 Earnings, Revenues Beat; Shares Rise - Analyst Blog Zacks
Feb-12-15 02:21PM  Shire says $1.6bn windfall from AbbVie is tax-free at Financial Times
01:30PM  AbbVie Seeks Japanese Approval for HCV Cocktail Treatment - Analyst Blog Zacks
10:45AM  Shire Moves Up On NPS Potential; Q4 Earnings Miss at Investor's Business Daily
09:30AM  The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead, AbbVie, Regeneron and Alkermes - Press Releases Zacks
Feb-11-15 10:04PM  AbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C PR Newswire
03:05PM  EMA Defends Controversial Decision to Redact Some AbbVie Trial Data at The Wall Street Journal
12:55PM  Yes, AbbVie is Still a Buy at
12:54PM  Deutsche Bank's 7 Reasons AbbVie Is Still A Buy Benzinga
11:47AM  Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog Zacks
10:03AM  Hey Abbvie, Don't Start What You Can't Finish Yahoo Finance Contributors
Feb-10-15 05:43PM  Unilife's unique delivery systems CNBC
Feb-09-15 11:46AM  Jefferies Analyst Says AbbVie Hepatitis C Price-War Fears Overblown Benzinga
11:05AM  AbbVie: Citigroup Says Not So Fast at
09:55AM  Will AbbVie (ABBV) Stock be Hurt Today by This Coverage Initiation? at TheStreet
09:45AM  UPDATE: Citi Initiates Coverage On AbbVie, Sees Price Erosion Ahead Benzinga
Feb-07-15 12:01AM  AbbVie: Big Pharma at a Discount Price at
Feb-06-15 05:47PM  Can Gilead Boost HCV Sales with Health Service Deals? - Analyst Blog Zacks
04:37PM  Equity markets ended the day lower... Yahoo Finance Contributors
03:19PM  Drug price battles CNBC
11:08AM  Will Reports of More Potential Pfizer Acquisitions Affect AbbVie (ABBV) Stock Today? at TheStreet
10:50AM  Gilead Sciences & AbbVie: The End of the Hepatitis-C Trade? at
Feb-05-15 03:18PM  No, the Gilead-AbbVie Price War Won't Derail the Pharmaceutical Rally at
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Biogen, Celgene, AbbVie and Gilead - Press Releases Zacks
Feb-04-15 04:44PM  AbbVie (ABBV) Stock Tumbled Today After BMO Price Target Decrease at TheStreet -7.69%
04:25PM  Amgen Reveals Positive Results on Biosimilar Candidate - Analyst Blog Zacks
03:47PM  Gilead Sciences: Look on the Bright Side? at
11:47AM  Biotech Stock Roundup: Biogen Impresses with 4Q Results, Gilead & AbbVie HCV Drugs in Focus - Analyst Blog Zacks
08:22AM  Merck says hepatitis C drugs to lose breakthrough status Reuters
08:14AM  Gilead Tops Q4 Earnings Estimates, 2015 Outlook Disappoints - Analyst Blog Zacks
Feb-03-15 07:15PM  Gilead Sciences Beats Q4 Earnings Estimates, GILD Falls on Revenue Outlook - Stocks in the News Zacks
06:15PM  Repros Files for Androxal in the U.S. for Hypogonadism - Analyst Blog Zacks
05:37PM  Roche's Anti-PDL1 Gets Breakthrough Status for Lung Cancer - Analyst Blog Zacks
04:55PM  Eli Lilly/Boehringer Type II Diabetes Drug Gains FDA Nod - Analyst Blog Zacks
01:52PM  Catamaran backs Gilead's hepatitis C treatment over AbbVie competitor Reuters
Feb-02-15 05:19PM  What to look for in Gilead earnings at MarketWatch
03:30PM  Will Gilead (GILD) Miss Q4 Earnings on Low HCV Drug Sales? - Analyst Blog Zacks
12:22PM  Gilead: Hepatitis C Sales Guidance for 2015 Focus of Tuesday's Earnings Report at TheStreet
11:46AM  Credit Suisse: Street Too Cautious On HCV After AbbVie Update at
11:18AM  UBS Thinks AbbVie's Valuation Is 'Interesting' Benzinga
09:46AM  Novo Nordisk's Q4 Earnings Rise Y/Y, Provides 2015 Outlook - Analyst Blog Zacks
Feb-01-15 08:05AM  Shire gets go-ahead to market binge-eating medicine at Financial Times
Jan-31-15 12:40AM  [$$] AbbVie Takes Hit After Expectations for Hepatitis C Treatment Disappoint at The Wall Street Journal
Jan-30-15 06:23PM  AbbVie Hepatitis C Drug Predictions Disappoint at The Wall Street Journal
06:00PM  Cramer: These boots were made for investing CNBC
06:00PM  AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan PR Newswire
05:51PM  Friday's Market Recap Yahoo Finance Contributors
04:50PM  Another absolutely wild day on Wall Street Yahoo Finance Contributors
04:37PM  AbbVie Shares Slump as Hepatitis C Projections Disappoint at Bloomberg
04:25PM  Mastercard and Amazon are big market movers AP
02:15PM  Abbvie (ABBV) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
01:24PM  AbbVie expects hep C drug sales to top $3 billion per year Reuters
12:49PM  Gilead Sciences v. AbbVie: Who's Winning the Hepatitis-C War? at
12:07PM  AbbVie reports better-than-expected 4Q on Humira sales AP
10:54AM  Eli Lilly's 4Q Earnings Beat, Revenue Outlook Lowered - Analyst Blog Zacks
10:50AM  AbbVie Q4 Earnings Beat Expectations on Humira Strength - Analyst Blog Zacks
10:10AM  Abbvie Expects $3B In Hepatitis C Drug Sales And 40% Of Insured Customers at Forbes
09:47AM  Q4 Earnings Tally, & What It Means - Ahead of Wall Street Zacks
09:20AM  AbbVie (ABBV) Tops 4Q Earnings Estimates, Affirms View - Tale of the Tape Zacks
09:00AM  AbbVie Inc Earnings Call scheduled for 9:00 am ET today CCBN
08:55AM  Are Humira Sales Enough to Lift AbbVie? at 24/7 Wall St.
08:42AM  Drugmaker AbbVie beats estimates as Humira sales rise Reuters
08:01AM  AbbVie reports 4Q loss AP
07:58AM  AbbVie shares up 2.6% as company beats profit, sales estimates at MarketWatch
07:58AM  ABBVIE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:47AM  AbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results PR Newswire
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 17Sale58.7024114,147106,592Feb 19 05:51 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 09Option Exercise24.072,25054,1643,168Feb 11 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Option Exercise24.078,495204,501188,563Dec 22 05:22 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Sale68.008,495577,660180,068Dec 22 05:22 PM
HURWICH THOMAS A.VP, ControllerNov 24Sale67.811,500101,71763,211Nov 26 05:00 PM
HURWICH THOMAS A.VP, ControllerNov 06Option Exercise24.0710,000240,73171,448Nov 07 05:57 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 04Sale51.204,799245,706395,403Mar 04 05:13 PM